DE2043971C3 - Antitumorsubstanz aus haemolytischen Streptococcen - Google Patents
Antitumorsubstanz aus haemolytischen StreptococcenInfo
- Publication number
- DE2043971C3 DE2043971C3 DE2043971A DE2043971A DE2043971C3 DE 2043971 C3 DE2043971 C3 DE 2043971C3 DE 2043971 A DE2043971 A DE 2043971A DE 2043971 A DE2043971 A DE 2043971A DE 2043971 C3 DE2043971 C3 DE 2043971C3
- Authority
- DE
- Germany
- Prior art keywords
- solution
- substance
- ammonium sulfate
- aqueous
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000126 substance Substances 0.000 title claims description 59
- 230000000259 anti-tumor effect Effects 0.000 title claims description 30
- 230000002949 hemolytic effect Effects 0.000 title claims description 12
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000003319 supportive effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 57
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 43
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 42
- 235000011130 ammonium sulphate Nutrition 0.000 description 42
- 239000000284 extract Substances 0.000 description 33
- 239000008055 phosphate buffer solution Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 230000005918 in vitro anti-tumor Effects 0.000 description 24
- 239000000843 powder Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 229920005654 Sephadex Polymers 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 239000012507 Sephadex™ Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000008176 lyophilized powder Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 241000193996 Streptococcus pyogenes Species 0.000 description 11
- 238000004140 cleaning Methods 0.000 description 11
- 239000010414 supernatant solution Substances 0.000 description 11
- 239000001506 calcium phosphate Substances 0.000 description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 description 10
- 235000011010 calcium phosphates Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000005185 salting out Methods 0.000 description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 7
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229910001651 emery Inorganic materials 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940009493 gel-one Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP44070283A JPS4843841B1 (en, 2012) | 1969-09-06 | 1969-09-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2043971A1 DE2043971A1 (de) | 1971-09-30 |
| DE2043971B2 DE2043971B2 (de) | 1978-11-23 |
| DE2043971C3 true DE2043971C3 (de) | 1979-07-12 |
Family
ID=13426989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2043971A Expired DE2043971C3 (de) | 1969-09-06 | 1970-09-04 | Antitumorsubstanz aus haemolytischen Streptococcen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3810819A (en, 2012) |
| JP (1) | JPS4843841B1 (en, 2012) |
| CA (1) | CA928236A (en, 2012) |
| DE (1) | DE2043971C3 (en, 2012) |
| FR (1) | FR2070674B1 (en, 2012) |
| GB (1) | GB1286014A (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271151A (en) | 1976-01-01 | 1981-06-02 | Kureha Kagaku Kogyo Kabushiki Kaisha | Protein-bound polysaccharides |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021541A (en) * | 1975-10-20 | 1977-05-03 | New York Medical College | Antigen isolated from group A (beta-hemolytic) streptococci and method for isolating the same |
| JPS5315495A (en) * | 1976-07-22 | 1978-02-13 | Kureha Chem Ind Co Ltd | Preparation of polysaccharides |
| DE2652684C3 (de) * | 1976-11-19 | 1982-03-25 | Lange, Kurt, New York, N.Y. | Wasserlösliches Protein (Antigen) aus β-hämolysierenden Streptokokken der Gruppe A |
| JPS557014A (en) * | 1978-06-29 | 1980-01-18 | Chugai Pharmaceut Co Ltd | Antitumor agent and its preparation |
| JPS55102596A (en) * | 1978-12-27 | 1980-08-05 | Meiji Seika Kaisha Ltd | Novel antibiotic substance, bn-183b substance, and its preparation |
| IL73883A (en) * | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
-
1969
- 1969-09-06 JP JP44070283A patent/JPS4843841B1/ja active Pending
-
1970
- 1970-09-03 GB GB42317/70A patent/GB1286014A/en not_active Expired
- 1970-09-04 DE DE2043971A patent/DE2043971C3/de not_active Expired
- 1970-09-04 CA CA092599A patent/CA928236A/en not_active Expired
- 1970-09-04 FR FR7032201A patent/FR2070674B1/fr not_active Expired
- 1970-09-04 US US00069774A patent/US3810819A/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271151A (en) | 1976-01-01 | 1981-06-02 | Kureha Kagaku Kogyo Kabushiki Kaisha | Protein-bound polysaccharides |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1286014A (en) | 1972-08-16 |
| FR2070674A1 (en, 2012) | 1971-09-17 |
| FR2070674B1 (en, 2012) | 1974-08-30 |
| DE2043971B2 (de) | 1978-11-23 |
| JPS4843841B1 (en, 2012) | 1973-12-21 |
| CA928236A (en) | 1973-06-12 |
| US3810819A (en) | 1974-05-14 |
| DE2043971A1 (de) | 1971-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3400413C2 (en, 2012) | ||
| DE2441454C3 (de) | Antileukämische proteinhaltige Fraktion und ihre Herstellung | |
| DE3402647A1 (de) | Verfahren zur gewinnung von koloniestimulierendem faktor und kallikrein aus menschlichem urin | |
| DE3421789C2 (en, 2012) | ||
| DE2043971C3 (de) | Antitumorsubstanz aus haemolytischen Streptococcen | |
| DE69411073T2 (de) | Medizinisches Bleichmittel | |
| EP0101063A2 (de) | Neues Polypeptid mit Wirkung auf das Immunsystem, Verfahren zu seiner Isolierung und Reinigung, seine Verwendung und dieses enthaltende Mittel | |
| DE2024586B2 (de) | Langsame a - und ß - Glykoproteine aus Mikrobenkörpern, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung | |
| DE2919132A1 (de) | Substanz ks-2-b, verfahren zu deren herstellung und diese substanz enthaltende mittel | |
| CH641354A5 (de) | Material mit antitumorwirkung und verfahren zu dessen herstellung. | |
| DE2605576C3 (de) | Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| DE1442134B2 (de) | In vivo antikoagulierend wirkendes und defibrinierendes Enzym | |
| EP0395851B1 (de) | Glykoproteine aus Avena sativa, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutischer Wirkstoff | |
| DE2152112C3 (de) | Impfstoff gegen Pseudomonas aeruginosa | |
| DE1617279C3 (de) | Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel | |
| CH639133A5 (de) | Verfahren zur herstellung einer antitumor wirksamen substanz mit immunostimulierender wirkung. | |
| DE2639410C2 (de) | Polypeptid VI-7501 mit Antitumorwirkung | |
| DE2508396A1 (de) | Verfahren zur gewinnung von virusproteinen, die dabei erhaltenen proteine und diese proteine als wirkstoffe enthaltende arzneimittel | |
| DE3873115T2 (de) | Polypeptid mit antiviraler wirkung, und seine anwendung. | |
| CH640865A5 (de) | Glykoproteid des menschlichen urins, verfahren zu seiner herstellung und mittel zur bekaempfung von leukozytopenie. | |
| DE2921829C2 (en, 2012) | ||
| DE2803681C2 (en, 2012) | ||
| DE2737943A1 (de) | Neue antibiotika, substanzen sf-1130- x tief 1 und -x tief 2 , verfahren zu ihrer herstellung und ihre verwendung | |
| DD273450A5 (de) | Verfahren zur gewinnung neuer polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |